KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Short term Debt (2016 - 2025)

AbbVie has reported Short term Debt over the past 14 years, most recently at $2.5 billion for Q4 2025.

  • Quarterly Short term Debt fell 63.27% to $2.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 billion through Dec 2025, down 63.27% year-over-year, with the annual reading at $2.5 billion for FY2025, 63.27% down from the prior year.
  • Short term Debt was $2.5 billion for Q4 2025 at AbbVie, up from $2.0 billion in the prior quarter.
  • Over five years, Short term Debt peaked at $12.6 billion in Q2 2024 and troughed at $1.0 million in Q1 2023.
  • The 5-year median for Short term Debt is $4.1 billion (2022), against an average of $5.1 billion.
  • Year-over-year, Short term Debt tumbled 99.99% in 2023 and then soared 1019200.0% in 2024.
  • A 5-year view of Short term Debt shows it stood at $14.0 million in 2021, then soared by 29435.71% to $4.1 billion in 2022, then skyrocketed by 73.91% to $7.2 billion in 2023, then decreased by 5.38% to $6.8 billion in 2024, then plummeted by 63.27% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Short term Debt are $2.5 billion (Q4 2025), $2.0 billion (Q3 2025), and $2.0 billion (Q2 2025).